New Double-Blind Clinical Trial: Oxaloacetate Improves Both Cognitive Performance and Physical Function in ME/CFS

A new randomized, double-blind clinical trial peer-reviewed and published by Frontiers in Neurology has demonstrated that oxaloacetate significantly improves cognitive function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), while also supporting improvements in physical activity.

This breakthrough adds to the growing body of research showing the ability of Oxaloacetate CFS, a medical food, to target both the mental and physical symptoms of ME/CFS. 

• Improved Cognitive Function: Patients receiving oxaloacetate showed significant improvements in cognitive performance over the 90-day study period. The control compound (placebo) did not produce these effects.
  

• Improved Physical Energy: Oxaloacetate patients experienced significant improvements in upright physical activity and reductions in fatigue.

“These promising findings show oxaloacetate working on two fronts simultaneously,” said Alan Cash, one of the study’s authors. “Improvements in cognition, coupled with gains in physical function, point toward a more comprehensive approach to treating ME/CFS.”

ME/CFS patients suffer from a combination of persistent fatigue, cognitive dysfunction, reduced physical activity and a sundry of other complex, interrelated symptoms that vary amongst the patient population. As most available therapies for ME/CFS target one domain, the results of this oxaloacetate study are particularly promising for the ME/CFS community, suggesting that oxaloacetate has the potential to provide integrated support for both body and brain.

The 90-day, randomized, double-blind, placebo-controlled clinical trial gave 82 ME/CFS patients either a control compound or 2,000 mg/day of Oxaloacetate CFS. The full study results from Frontiers in Neurology and all published, peer-reviewed data can be viewed here.